Experienced biopharmaceutical industry analyst, reporter & commentator following strategic, commercial and scientific issues affecting the sector. Regular contributor to Nature Biotechnology, Informa Business Intelligence (IN VIVO, Datamonitor, Scrip) and EY Life Sciences. Specialist & feature coverage and consulting across market access, pricing, outcomes-based care, precision medicine, digital health, AI, R&D strategies and consumer empowerment for a range of clients in biopharma and investment community.
Latest From Melanie Senior
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda?
Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.
Verona Pharma’s Phase III ensifentrine, if approved, would be the first new dual-mechanism treatment class for COPD patients in decades. It could propel the UK-based biotech toward profitability, or into the arms of a larger partner.
Germany is drastically squeezing orphan drug pricing while new US laws protect rare diseases drugs from price negotiations. These contrasting moves fuel the longstanding debate over whether orphans still deserve special incentives.
Deals show large investors’ appetite for early-stage biotech, but can VC and PE rub along?